Trials / Completed
CompletedNCT00234520
A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide
A Multicentre Prospective Controlled Observer Blinded Cohort Study in Patients With Acromegaly to Evaluate the Risk of Cardiac Valvular Regurgitation in Patients Treated With Lanreotide Relative to Patients Treated With Octreotide
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 225 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to compare the risk of acromegaly patients developing valvular regurgitation when receiving lanreotide or octreotide
Conditions
Timeline
- Start date
- 2003-05-01
- Primary completion
- 2005-02-18
- Completion
- 2005-02-18
- First posted
- 2005-10-07
- Last updated
- 2019-08-02
Locations
33 sites across 10 countries: Belgium, Czechia, Denmark, France, Hungary, Italy, Poland, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00234520. Inclusion in this directory is not an endorsement.